Adjunctive Sarcosine plus Benzoate Improved Cognitive Function in Chronic Schizophrenia Patients with Constant Clinical Symptoms: A Randomised, Double-Blind, Placebo-Controlled Trial
學年 105
學期 2
出版（發表）日期 2017-06-01
作品名稱 Adjunctive Sarcosine plus Benzoate Improved Cognitive Function in Chronic Schizophrenia Patients with Constant Clinical Symptoms: A Randomised, Double-Blind, Placebo-Controlled Trial
作品名稱（其他語言）
著者 Chun-Yuan Lin; Sun-Yuan Liang; Yue-Cung Chang; Shuo-Yen Ting; Ching-Ling Kao; Yu-Hsin Wu; Guochuan Tsai; Hsien-Yuan Lane
單位
出版者
著錄名稱、卷期、頁數 The World Journal of Biological Psychiatry 18(5), p.357-368
摘要 Objectives Hypofunction of NMDA receptor is implicated in the pathophysiology, particularly cognitive impairment, of schizophrenia. Sarcosine, a glycine transporter I (GlyT-1) inhibitor, and sodium benzoate, a d-amino acid oxidase (DAAO) inhibitor, can both enhance NMDA receptor-mediated neurotransmission. We proposed simultaneously inhibiting DAAO and GlyT-1 may be more effective than inhibition of either in improving the cognitive and global functioning of schizophrenia patients. Methods This study compared add-on sarcosine (2 g/day) plus benzoate (1 g/day) vs. sarcosine (2 g/day) for the clinical symptoms, as well as the cognitive and global functioning, of chronic schizophrenia patients in a 12-week, double-blind, randomised, placebo-controlled trial. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12. Results Adjunctive sarcosine plus benzoate, but not sarcosine alone, improved the cognitive and global functioning of patients with schizophrenia, even when their clinical symptoms had not improved. Conclusions This finding suggests N-methyl-d-aspartate receptor-enhancement therapy can improve the cognitive function of patients with schizophrenia, further indicating this pro-cognitive effect can be primary without improvement in clinical symptoms.
關鍵字 Schizophrenia;biological psychiatry;psychopharmacology;cognitive function;NMDA receptor
語言 en
ISSN
期刊性質 國外
收錄於 SCI
產學合作
通訊作者
審稿制度 否
國別 GBR
公開徵稿
出版型式 ,紙本
相關連結

機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/112720 )

SDGS 良好健康和福祉